TY - JOUR
T1 - Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators
AU - Shepherd, Bryan E.
AU - Sterling, Timothy R.
AU - Moore, Richard D.
AU - Raffanti, Stephen P.
AU - Hulgan, Todd
N1 - Funding Information:
Financial support: Vanderbilt-Meharry Center for AIDS Research (NIH program 930 AI54999) and National Institutes of Health (grant K23 AT002508-01 to T.H., grant K24 A1065298 to T.R.S., and grants K24 DA00432 and R01 DA11602 to R.D.M.)
PY - 2009/7
Y1 - 2009/7
N2 - Objective: To evaluate a model for predicting time to AIDS or death among HIV-infected persons initiating highly active antiretroviral therapy (HAART). Study Design and Setting: The model was constructed from 1,891 HAART initiators in the Collaborations in HIV Outcomes Research/US (CHORUS) cohort. The model's predictive ability was assessed using internal bootstrap validation techniques and data from 716 HAART initiators at Johns Hopkins HIV Clinical Cohort (JHHCC) in whom HIV disease was, in general, more advanced. Results: The estimated concordance statistic was 0.632 with the bootstrap method and 0.625 in JHHCC. Mean predicted and observed 3-year AIDS-free survival for JHHCC was 0.76 and 0.73 (95% confidence interval [CI], 0.69-0.77), respectively; mean predicted and observed 5-year AIDS-free survival was 0.69 and 0.57 (95% CI, 0.52-0.62), respectively. Sensitivity analyses showed that the discrepancy between predicted and observed AIDS-free survival after 3 years could be due to differences in lost-to-follow-up rates between cohorts. Conclusion: The model was fair at using baseline characteristics to order patients' risk of disease progression, but did not accurately predict AIDS-free survival >3 years after HAART initiation. Different variable definitions, patient characteristics, and loss to follow-up highlight the challenges of using data from one cohort to predict AIDS-free survival in an independent cohort.
AB - Objective: To evaluate a model for predicting time to AIDS or death among HIV-infected persons initiating highly active antiretroviral therapy (HAART). Study Design and Setting: The model was constructed from 1,891 HAART initiators in the Collaborations in HIV Outcomes Research/US (CHORUS) cohort. The model's predictive ability was assessed using internal bootstrap validation techniques and data from 716 HAART initiators at Johns Hopkins HIV Clinical Cohort (JHHCC) in whom HIV disease was, in general, more advanced. Results: The estimated concordance statistic was 0.632 with the bootstrap method and 0.625 in JHHCC. Mean predicted and observed 3-year AIDS-free survival for JHHCC was 0.76 and 0.73 (95% confidence interval [CI], 0.69-0.77), respectively; mean predicted and observed 5-year AIDS-free survival was 0.69 and 0.57 (95% CI, 0.52-0.62), respectively. Sensitivity analyses showed that the discrepancy between predicted and observed AIDS-free survival after 3 years could be due to differences in lost-to-follow-up rates between cohorts. Conclusion: The model was fair at using baseline characteristics to order patients' risk of disease progression, but did not accurately predict AIDS-free survival >3 years after HAART initiation. Different variable definitions, patient characteristics, and loss to follow-up highlight the challenges of using data from one cohort to predict AIDS-free survival in an independent cohort.
KW - AIDS
KW - Antiretroviral therapy
KW - Bootstrap
KW - CD4 lymphocyte percent
KW - Heterogeneity
KW - Loss to follow-up
KW - Validation
UR - http://www.scopus.com/inward/record.url?scp=67349156426&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349156426&partnerID=8YFLogxK
U2 - 10.1016/j.jclinepi.2008.09.002
DO - 10.1016/j.jclinepi.2008.09.002
M3 - Article
C2 - 19108987
AN - SCOPUS:67349156426
SN - 0895-4356
VL - 62
SP - 729
EP - 737
JO - Journal of Clinical Epidemiology
JF - Journal of Clinical Epidemiology
IS - 7
ER -